@Article{,
AUTHOR = {Tom Pickles, Alan Pollack},
TITLE = {The case for dose escalation versus adjuvant androgen deprivation therapy for intermediate risk prostate cancer},
JOURNAL = {Canadian Journal of Urology},
VOLUME = {13},
YEAR = {2006},
NUMBER = {Suppl.2},
PAGES = {68--71},
URL = {http://www.techscience.com/CJU/v13nSuppl.2/63358},
ISSN = {1488-5581},
ABSTRACT = {Patients with intermediate-risk prostate cancer have a
significant risk of biochemical failure after treatment with
external beam radiation therapy. Two strategies to improve
outcomes are radiation dose escalation and androgen
deprivation therapy (ADT). This article discusses the
evidence in favor of dose escalation.<br/>
The case for radiation dose escalation has been established
by several randomized studies, which show improved
biochemical control (bNED) rates. Although late toxicity
was also increased, it remains at clinically acceptable levels.
The use of more focal methods of radiation, such as proton
therapy and intensity modulated radiation therapy (IMRT),
allows safe dose escalation to 80 Gy. The role of adjuvant
ADT is most clearly established in high-risk disease.
Advantages in the intermediate-risk group are less
pronounced. It is probable that therapeutic gain seen from
dose escalation in intermediate-risk patients might allow
them to be spared the toxicity of ADT and yet achieve good
PSA and clinical control rates. Further randomized trials
comparing and or combining the two treatment strategies
are required.},
DOI = {}
}